Vertex Pharmaceuticals (VRTX)
Health Care6 articles
Price chart
Why is VRTX moving today?
-1.8%VRTX is -1.8% today, inside the ordinary range for a session (under 3%). No stories about it reached the feed in the last 24 hours.
What this does not prove. A story on the same day is evidence of timing, not of cause: it explains a move only if it accounts for the size and the direction, and most single-stock moves carry a sector or index component too. Nothing here is a forecast.
Source: Yahoo Finance - quote as of 2 days ago
Vertex Pharmaceuticals (VRTX) overview
Vertex Pharmaceuticals is a biotech known for its cystic-fibrosis therapies.
VRTX is a member of the S&P 500. It sits in the Health Care sector. That sector covers pharmaceutical, biotech, device and managed-care companies.
Vertex Pharmaceuticals trades on the NasdaqGS under the ticker symbol VRTX. The most recent market data puts the share price at about $499.74. That is down 1.77% on the session. At that price the company is worth roughly $126.66B.
Over the past 52 weeks, VRTX has traded between $403.16 and $560.25. Shares change hands at a trailing price-to-earnings (P/E) ratio of about 28.9. The P/E ratio sets the share price against a year of earnings. A higher number means the market is paying more for each dollar the company earns.
Key statistics
Source: Yahoo Finance - quote as of 2 days ago
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Why investors watch VRTX
VRTX is one of the larger names in the Health Care sector, so investors follow it closely. It tends to move with the rest of the sector. This page sums up each VRTX story as it breaks, and tags it bullish, bearish or neutral.
Size matters here as well. The S&P 500 is weighted by market value. VRTX is large enough that its own share price nudges the whole index. So it is worth watching even for investors who only hold index funds.
What moves VRTX
- Earnings. VRTX reports results four times a year. A surprise against the estimate tends to move the stock that day.
- Analyst calls. Upgrades, downgrades and new price targets change what the market expects from VRTX.
- Sector news. Health Care stocks often move together, so a rival's news can move VRTX too.
- Index weight. VRTX is big enough to move the S&P 500 on its own.
Market Mood
Latest VRTX news
10% of Cystic Fibrosis Patients Still Await Effective Treatment
Approximately 10% of cystic fibrosis patients do not benefit from recent advancements in CF treatments, which use drugs like Trikafta. These drugs, made by Vertex Pharmaceuticals, enhance the CFTR protein function for 90% of patients, transforming the disease into a more manageable condition. However, the remaining 10% of patients, born with other genetic mutations, experience a lack of effective treatment. Recent scientific efforts, including attempts by Vertex and Moderna using mRNA technology and Boehringer Ingelheim's gene therapy trials, were halted due to tolerability issues and other challenges. Emily's Entourage, a nonprofit founded by Emily Kramer-Golinkoff, has played a key role in continuing research for these patients. Since its inception in 2011, it has raised over $22 million, funding 51 research projects that explore novel treatments like antisense oligonucleotides and small molecules. Delivering drugs to affected lung cells poses significant scientific challenges because of the lungs' natural defenses and the presence of thick mucus in CF patients. This matters to ordinary investors as ongoing research might open opportunities for pharmaceutical companies to address the unmet needs of these patients, potentially leading to breakthroughs that could impact company valuations and future investment decisions.
Read More: 10% of Cystic Fibrosis Patients Still Await Effective Treatment
Vertex (VRTX) Named Top Biotech Stock After Rival Drug Fails
Bernstein has identified Vertex Pharmaceuticals (VRTX) as its top biotechnology stock pick following the failure of a competing drug. This development is significant for investors as it highlights Vertex's competitive positioning in the market. The analyst report suggests that this could boost Vertex's stock performance amid shifts in the biotech sector. Observers should monitor how this news affects trading volumes for Vertex shares moving forward.
Read More: Vertex (VRTX) Named Top Biotech Stock After Rival Drug Fails
XLV vs PBE: Comparing Two Healthcare ETFs for Investors
The State Street Health Care Select Sector SPDR ETF (XLV) has an expense ratio of 0.08% and offers a yield of 1.6%, while the Invesco Biotechnology & Genome ETF (PBE) has a 0.58% expense ratio and a yield of 1.7%. XLV includes 60 holdings like Eli Lilly & Co (NYSE:LLY) at 16.5% and Johnson & Johnson (NYSE:JNJ) at 10.6%. In contrast, PBE holds 30 companies, with Vertex Pharmaceuticals (NASDAQ:VRTX) at 5.2% and Biogen Inc (NASDAQ:BIIB) at 5.1%. This comparison helps investors weigh low-cost sector exposure versus targeted growth potential in biotechnology.
Read More: XLV vs PBE: Comparing Two Healthcare ETFs for Investors
Vertex (VRTX) Stock Rating Reiterated After Crinetics Deal
Canaccord has reiterated its rating for Vertex Pharmaceuticals (VRTX) following the company's deal with Crinetics Pharmaceuticals. This decision reflects confidence in Vertex's growth potential influenced by strategic partnerships. Market analysts point out that such collaborations can significantly enhance Vertex's product pipeline and leverage its position in the biopharmaceutical space. For investors, understanding analyst ratings and strategic moves like this can provide insights into potential stock performance.
Read More: Vertex (VRTX) Stock Rating Reiterated After Crinetics Deal
Vertex Pharmaceuticals (VRTX) Form 144 Filed on June 18
Vertex Pharmaceuticals Inc. (VRTX) filed Form 144 on June 18, which allows for the sale of restricted securities. The form indicates that there may be upcoming stock sales by the company's affiliates. Such filings are essential as they provide transparency regarding insider trading activities and can impact investor sentiment. Understanding the details of these transactions can help investors gauge market movements and the potential supply of shares.
Read More: Vertex Pharmaceuticals (VRTX) Form 144 Filed on June 18
Premarket Movers: Kohl's, Casey's, and Vertex Show Significant Activity
In early trading, Kohl's, Casey's General Stores, and Vertex Pharmaceuticals emerged as the stocks with the largest price movements. Such fluctuations are significant as they can indicate investor sentiment and potential shifts in market trends. Increased volatility in these stocks may attract attention from traders looking for short-term gains, impacting overall market liquidity. Monitoring these movements could provide insights into retail and pharmaceutical sectors.
Read More: Premarket Movers: Kohl's, Casey's, and Vertex Show Significant ActivityMore Health Care stocks
Frequently asked questions
Is Vertex Pharmaceuticals in the S&P 500?
Yes. Vertex Pharmaceuticals trades as VRTX and is a member of the S&P 500. The index lists it in the Health Care sector.
What sector is VRTX in?
VRTX sits in the Health Care sector of the S&P 500.
Where can I find the latest VRTX news?
Right here. This page collects recent VRTX news and market analysis. Every story gets an AI summary and a bullish, bearish or neutral tag.
What is Vertex Pharmaceuticals's stock price?
VRTX last traded at about $499.74. Prices move all through the session, so this is the latest quote rather than a live one.
What is Vertex Pharmaceuticals's market cap?
VRTX is worth roughly $126.66B. Market cap is the share price times the number of shares outstanding.
What is VRTX's P/E ratio?
VRTX trades at a trailing P/E ratio of about 28.9. The ratio compares the share price with earnings per share over the past year.